Watch CPMD. Know when insiders buy.
One email the day a filing lands. Free.
CPMD
CANNAPHARMARX, INC.
0.00
+0.00 +0.00%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.7MP/E —DIV YIELD —FCF YIELD —REV TTM $1.7M +24.8%NET INCOME −$11.3MNET DEBT $7M52W 0.00 – 0.01SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $276K | +19.3% | -50.1% | −$379K | −$1.9M | — | 0.00 | −$127K | — | — | Aug 18 |
| Q1 2026 · Mar 31 | $627K | +87.1% | -65.3% | −$682K | −$382K | — | 0.00 | −$244K | — | — | May 20 |
| Q4 2025 · Dec 31derived | $139K | −71.2% | -375.9% | −$894K | −$7.5M | — | -0.01 | $1.1M | — | — | Aug 18 |
| Q3 2025 · Sep 30 | $657K | +110.3% | -67.0% | −$936K | −$1.5M | −884.3% | 0.00 | −$803K | — | — | Nov 14 |
| Q2 2025 · Jun 30 | $232K | — | -268.2% | −$841K | −$1.4M | −126.4% | 0.00 | −$446K | — | — | Aug 18 |
| Q1 2025 · Mar 31 | $335K | +1197.7% | -149.9% | −$678K | −$691K | — | 0.00 | −$601K | — | — | May 20 |
| Q4 2024 · Dec 31 | $482K | — | -350.7% | −$1.5M | −$3.7M | −149.6% | -0.01 | −$180K | $0 | −$180K | Mar 31 |
| Q3 2024 · Sep 30 | $312K | — | -114.1% | −$516K | $188K | — | 0.00 | −$541K | — | — | Nov 14 |
| Q2 2024 · Jun 30 | $0 | — | — | −$518K | $5.4M | — | 0.01 | −$428K | — | — | Aug 14 |
| Q1 2024 · Mar 31 | $26K | — | -1692.8% | −$790K | −$11.7M | — | -0.03 | −$549K | $0 | −$549K | May 16 |
| Q4 2023 · Dec 31derived | $0 | — | — | $700K | $7.5M | — | 0.02 | −$1.3M | $2K | −$1.3M | Apr 10 |
| Q3 2023 · Sep 30 | $0 | — | — | −$667K | −$564K | — | 0.00 | $124K | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.4M | -153.1% | −$3.3M | −$11.1M | -817.2% | -0.02 | −$789K | $6K | −$795K | — | — |
| FY2024 · to Dec 31 | $820K | -357.9% | −$3.6M | −$9.9M | -1207.8% | -0.02 | −$1.7M | $0 | −$1.7M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$1.6M | $3.7M | — | 0.01 | −$2.3M | $81K | −$2.4M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$5.2M | −$8.5M | — | 0.04 | −$1.4M | — | — | — | — |
| FY2021 · to Dec 31 | $0 | — | −$3M | −$8.8M | — | 0.12 | −$2.4M | — | — | — | — |
| FY2020 · to Dec 31 | $0 | — | −$14.5M | −$19.9M | — | — | −$564K | — | — | $0 | — |
Every number comes from CANNAPHARMARX, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.